Search Results
May 27, 2026, 05:41 ET Bulletin from the Extraordinary General Meeting of AB Electrolux
AMN 2026:03). The resolution of the General Meeting as described above was adopted as one resolution.Minutes from the Extraordinary General Meeting
More news about: Electrolux Group
May 27, 2026, 05:36 ET Bulletin from the Extraordinary General Meeting of AB Electrolux
AMN 2026:03). The resolution of the General Meeting as described above was adopted as one resolution.Minutes from the Extraordinary General Meeting
More news about: Electrolux Group
May 21, 2026, 07:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
May 07, 2026, 11:03 ET Generations Retirement Group Expands Outreach to Massachusetts Nurses
AMN Healthcare, approximately 33% of the nursing workforce is eligible or nearing eligibility for retirement, while 40% of registered nurses indicate
More news about: Generations Retirement Group
May 05, 2026, 07:05 ET Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 23, 2026, 12:09 ET Electrolux Group accelerates profitable growth strategy through a partnership with Midea, global organization and footprint optimization, and a fully underwritten rights issue of approx. SEK 9 billion
disregarded. Investor AB's guarantee undertaking is conditional upon said majority being received at the EGM.The Swedish Securities Council's ruling (AMN 2026:03) will be made available on the Swedish Securities Council's website (
More news about: Electrolux Group
Apr 23, 2026, 12:05 ET Electrolux Group accelerates profitable growth strategy through a partnership with Midea, global organization and footprint optimization, and a fully underwritten rights issue of approx. SEK 9 billion
disregarded. Investor AB's guarantee undertaking is conditional upon said majority being received at the EGM.The Swedish Securities Council's ruling (AMN 2026:03) will be made available on the Swedish Securities Council's website (
More news about: Electrolux Group
Apr 22, 2026, 16:35 ET Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 10, 2026, 07:30 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Apr 09, 2026, 19:50 ET Zebra Technologies and Aiva Health Announce Partnership to Power Hands-Free Nurse Workflows
via ServiceNow®Access to Clinical Policies & ProceduresVoice-initiation of Clinical Interpretation Sessions: LanguageLine® and AMN Healthcare®When paired with Zebra's HC20/HC50 mobile computers, nurses can use Aiva alongside familiar mobile workflows. With Zebra's new
More news about: Aiva, Inc.
Apr 01, 2026, 16:15 ET SIKORA Unveils Three New Product Innovations for the Wire and Cable Industry
Pulverizing Systems, Recycling Systems and Measurement & Control Systems divisions consolidate the many years of experience and in-depth know-how of the AMN, AUTOMATIK, ETTLINGER, GALA, MAAG, REDUCTION, SCHEER, SIKORA, WITTE and XANTEC product brands. The MAAG Group currently employs over 1,900 people at
More news about: Dover
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Mar 24, 2026, 09:00 ET Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
report seeing more AI-informed patients over the past year. Access is a key driver: with national wait times exceeding 31 days on average (source: AMN Healthcare), 65% of patients say they've used AI because it's easier than seeing a doctor.Yet many patients aren't telling their doctors.
More news about: Zocdoc
Mar 24, 2026, 09:00 ET Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
report seeing more AI-informed patients over the past year. Access is a key driver: with national wait times exceeding 31 days on average (source: AMN Healthcare), 65% of patients say they've used AI because it's easier than seeing a doctor.Yet many patients aren't telling their doctors.
More news about: Zocdoc
Mar 17, 2026, 15:02 ET Group Management Services Appoints Beth Harhai as Chief Revenue Officer to Drive Strategic Growth
advising on go‑to‑market strategy for an emerging health‑tech company.Previously, Harhai held senior leadership roles at organizations including AMN Healthcare, where she oversaw a national sales organization, as well as DeliverHealth, Blackbaud, Healthgrades (acquired by WebMD), and Allscripts.
More news about: Group Management Services, Inc.
Mar 05, 2026, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Feb 04, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 07, 2026, 07:00 ET Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 16:03 ET Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Dec 10, 2025, 08:00 ET Trend Micro Honors Global Leaders in Cybersecurity with 2025 Global Customer Awards
realize this strategy and vision. Now we have a single pane of glass view, and one click control that wasn't possible before."Mani Masood, CISO, AMN Healthcare: "Cyber resilience is built by anticipating change before it becomes a crisis. Security leadership is the ability to make tomorrow's risks
More news about: Trend Micro Incorporated